Data from 76 patients over 3 years confirms value of assay of cell-mediated
BOSTON, April 11 /PRNewswire/ -- Results of an analysis of three years of data on the monitoring of cell-mediated immunity (CMI) in adult patients undergoing heart transplantation at the University of California at Los Angeles (UCLA) Health System have demonstrated that ImmuKnow(R) values appear to closely reflect the immune function of the transplant recipient and patient risk for organ rejection and/or infection. These data were presented today by Dr. Jon Kobashigawa at the annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) in Boston, MA.
"Based on our experience with the ImmuKnow assay we believe it is possible to assess the probability that specific patients are at risk for organ rejection or infection," stated Dr. Kobashigawa.
Between 2005 and 2007 Dr. Kobashigawa and his colleagues studied the immune function of 76 adult heart transplant patients. A total of 170 ImmuKnow assays were carried out in these patients between 12 and 365 days after transplantation. Levels of cell-mediated immunity (CMI) were classified as low (<225 ng/mL ATP), moderate (225-525 ng/mL ATP) or strong (>525 ng/mL ATP). In these patients, the mean CMI was 305 ng/mL of ATP with a standard deviation of + 153 ng/mL ATP. All patients were treated with tacrolismus, mycophenolate, and corticosteroids to lower the potential risk of organ rejection.
In follow-up analysis of the available data, Kobashigawa et al. were able to document five biopsy-proven organ rejections in patients with stronger immune function ( CMI > 300 ng/mL ATP; based on 74 assays) as compared to no rejections in patients with lower immune function (CMI < 300 ng/mL ATP; based on 96 assays). This difference was statistically significant (p < 0.001).
The average measure of immune function during rejection was also
|SOURCE Cylex Inc.|
Copyright©2008 PR Newswire.
All rights reserved